0 (0%) | 06-28 18:07 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 204.04 | 1-year : | 209.69 |
Resists | First : | 174.69 | Second : | 179.52 |
Pivot price | 172.58 | |||
Supports | First : | 166.86 | Second : | 138.83 |
MAs | MA(5) : | 170.23 | MA(20) : | 172.73 |
MA(100) : | 149.67 | MA(250) : | 143.1 | |
MACD | MACD : | 1.5 | Signal : | 2.8 |
%K %D | K(14,3) : | 11.4 | D(3) : | 13.9 |
RSI | RSI(14): 49.4 | |||
52-week | High : | 179.52 | Low : | 116.41 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BAP ] has closed above bottom band by 21.5%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 171.47 - 172.6 | 172.6 - 173.63 |
Low: | 165.2 - 166.66 | 166.66 - 167.98 |
Close: | 167.19 - 169.47 | 169.47 - 171.54 |
Fri, 22 Sep 2023
Abpro inks SPAC deal to fund bispecific R&D years after axed IPO - Fierce Biotech
Thu, 22 Sep 2022
Abpro partners with Celltrion to advance ABP-102, a bispecific antibody for HER2+ cancers - BioWorld Online
Wed, 21 Sep 2022
Celltrion partners with Abpro of U.S. for breast cancer treatment development - Yonhap News Agency
Wed, 21 Sep 2022
Abpro inks potential $1.75B deal with Celltrion for HER2+ cancer therapy - BioWorld Online
Wed, 21 Sep 2022
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer ... - Business Wire
Tue, 02 Feb 2021
Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300 ... - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 80 (M) |
Shares Float | 52 (M) |
Held by Insiders | 34.4 (%) |
Held by Institutions | 72.1 (%) |
Shares Short | 535 (K) |
Shares Short P.Month | 393 (K) |
EPS | 16.2 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 408.32 |
Profit Margin | 30 % |
Operating Margin | 36.9 % |
Return on Assets (ttm) | 2 % |
Return on Equity (ttm) | 15.8 % |
Qtrly Rev. Growth | 1.8 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 203.44 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -16.4 % |
Operating Cash Flow | 1,810 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 10.45 |
PEG Ratio | 8.4 |
Price to Book value | 0.41 |
Price to Sales | 0.83 |
Price to Cash Flow | 7.44 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |